Therapy Sculpts the Complex Interplay Between Cancer and the Immune System During Tumour Evolution

Overview

Journal Genome Med

Publisher Biomed Central

Specialty Genetics

Date 2022 Dec 8

PMID 36476325

Authors

Kerstin Thol

Piotr Pawlik

Nicholas McGranahan

Affiliations

Soon will be listed here.

Abstract

Cancer development is an evolutionary process. A key selection pressure is exerted by therapy, one of the few players in cancer evolution that can be controlled. As such, an understanding of how treatment acts to sculpt the tumour and its microenvironment and how this influences a tumour's subsequent evolutionary trajectory is critical. In this review, we examine cancer evolution and intra-tumour heterogeneity in the context of therapy. We focus on how radiotherapy, chemotherapy and immunotherapy shape both tumour development and the environment in which tumours evolve and how resistance can develop or be selected for during treatment.

Citing Articles

Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.

Wu Y, Shang J, Zhang X, Li N J Nanobiotechnology. 2024; 22(1):783.

PMID: 39702277 PMC: 11657939. DOI: 10.1186/s12951-024-02940-4.

Life history dynamics of evolving tumors: insights into task specialization, trade-offs, and tumor heterogeneity.

Ahmed M, Kim D Cancer Cell Int. 2024; 24(1):364.

PMID: 39506763 PMC: 11539310. DOI: 10.1186/s12935-024-03538-4.

A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens.

Martinez R, Finocchiaro C, Delhaye L, Gysens F, Anckaert J, Trypsteen W Front Immunol. 2024; 15:1444886.

PMID: 39497819 PMC: 11532180. DOI: 10.3389/fimmu.2024.1444886.

Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response.

Chen S, Xie D, Li Z, Wang J, Hu Z, Zhou D Commun Biol. 2024; 7(1):770.

PMID: 38918569 PMC: 11199503. DOI: 10.1038/s42003-024-06460-7.

Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden.

Gorlov I, Gorlova O, Tsavachidis S, Amos C Sci Rep. 2024; 14(1):12732.

PMID: 38831004 PMC: 11148192. DOI: 10.1038/s41598-024-63468-z.

References

Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S . Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019; 9(1):6136. PMC: 6467894. DOI: 10.1038/s41598-019-42237-3. View

Davila M, Brentjens R . CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016; 14(10):802-808. PMC: 5536094. View

Angka L, Martel A, Kilgour M, Jeong A, Sadiq M, de Souza C . Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. Ann Surg Oncol. 2018; 25(12):3747-3754. DOI: 10.1245/s10434-018-6691-3. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

Saddawi-Konefka R, OFarrell A, Faraji F, Clubb L, Allevato M, Jensen S . Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun. 2022; 13(1):4298. PMC: 9314425. DOI: 10.1038/s41467-022-31941-w. View

Gerstung M, Jolly C, Leshchiner I, Dentro S, Gonzalez S, Rosebrock D . The evolutionary history of 2,658 cancers. Nature. 2020; 578(7793):122-128. PMC: 7054212. DOI: 10.1038/s41586-019-1907-7. View

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

10.

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

11.

Li L, Zhang X, Wang X, Kim S, Herndon J, Becker-Hapak M . Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Med. 2021; 13(1):56. PMC: 8059244. DOI: 10.1186/s13073-021-00872-4. View

12.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

13.

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

14.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

17.

Ozcan M, Janikovits J, von Knebel Doeberitz M, Kloor M . Complex pattern of immune evasion in MSI colorectal cancer. Oncoimmunology. 2018; 7(7):e1445453. PMC: 5993484. DOI: 10.1080/2162402X.2018.1445453. View

18.

White M, Sloane R, Witt R, Reuben A, Gaudreau P, Andrews M . Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. Oncoimmunology. 2021; 10(1):1992880. PMC: 8583008. DOI: 10.1080/2162402X.2021.1992880. View

19.

Lee-Six H, Olafsson S, Ellis P, Osborne R, Sanders M, Moore L . The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019; 574(7779):532-537. DOI: 10.1038/s41586-019-1672-7. View

20.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View